Wakefield D, Jennings A, McCluskey P J
School of Pathology University of New South Wales, Department of Ophthalmology, St Vincent's Hospital, Sydney, Australia.
Clin Exp Ophthalmol. 2000 Apr;28(2):103-6. doi: 10.1046/j.1442-9071.2000.00282.x.
To demonstrate the safety and effectiveness of intravenous methylprednisolone (IVMP) in the treatment of uveitis in association with multiple sclerosis (MS).
Uveitis is an unusual manifestation of MS that may be severe, chronic and require systemic immunosuppression therapy. High-dose IVMP has previously been shown to be effective in the treatment of inflammatory eye disease and MS. Eight episodes of uveitis in five patients with MS were treated over a 10-year period in an open, uncontrolled trial. Two patients had chronic anterior uveitis, one patient had bilateral panuveitis and two patients had intermediate uveitis.
All patients responded to IVMP with evidence of a decrease in intraocular inflammatory activity and improved visual acuity (VA) within 2 weeks of commencing treatment. There were no severe ocular or systemic steroid side effects.
Intravenous methylprednisolone is an effective, well-tolerated form of therapy for uveitis in patients with MS.
证明静脉注射甲泼尼龙（IVMP）治疗与多发性硬化症（MS）相关的葡萄膜炎的安全性和有效性。
葡萄膜炎是MS的一种不常见表现，可能严重、慢性且需要全身免疫抑制治疗。高剂量IVMP先前已被证明对治疗炎症性眼病和MS有效。在一项为期10年的开放、非对照试验中，对5例MS患者的8次葡萄膜炎发作进行了治疗。2例患者患有慢性前葡萄膜炎，1例患者患有双侧全葡萄膜炎，2例患者患有中间葡萄膜炎。
所有患者对IVMP均有反应，在开始治疗后2周内有眼内炎症活动减轻和视力（VA）改善的证据。没有严重的眼部或全身类固醇副作用。
静脉注射甲泼尼龙是治疗MS患者葡萄膜炎的一种有效且耐受性良好的治疗方式。
